Last reviewed · How we verify
Eylea® Solution for intravitreal injection
Eylea (aflibercept) binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye.
Eylea (aflibercept) binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.
At a glance
| Generic name | Eylea® Solution for intravitreal injection |
|---|---|
| Sponsor | Rophibio, Inc. |
| Drug class | VEGF inhibitor / Antiangiogenic agent |
| Target | VEGF-A, VEGF-B, PlGF (placental growth factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Aflibercept is a soluble decoy receptor that acts as a VEGF trap, sequestering VEGF-A, VEGF-B, and PlGF in the vitreous. By preventing these growth factors from binding to their native receptors on endothelial cells, it reduces pathological neovascularization and vascular permeability in retinal diseases. This mechanism halts the progression of vision-threatening conditions driven by excessive angiogenesis.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Macular edema following retinal vein occlusion
- Diabetic macular edema
- Diabetic retinopathy
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
- Retinal detachment
Key clinical trials
- A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration (PHASE3)
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 (PHASE3)
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 (PHASE3)
- A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration (PHASE2)
- Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (PHASE3)
- Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (PHASE3)
- Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept (PHASE4)
- A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eylea® Solution for intravitreal injection CI brief — competitive landscape report
- Eylea® Solution for intravitreal injection updates RSS · CI watch RSS
- Rophibio, Inc. portfolio CI